Lepu Biopharma Co., Ltd. (2157.HK)
- Previous Close
4.360 - Open
4.450 - Bid 4.410 x --
- Ask 4.430 x --
- Day's Range
4.380 - 4.760 - 52 Week Range
2.160 - 5.430 - Volume
17,834,000 - Avg. Volume
18,670,565 - Market Cap (intraday)
7.544B - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.260 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China.
www.lepubiopharma.comRecent News: 2157.HK
View MorePerformance Overview: 2157.HK
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2157.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2157.HK
View MoreValuation Measures
Market Cap
7.46B
Enterprise Value
7.88B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.49
Price/Book (mrq)
9.79
Enterprise Value/Revenue
19.76
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-111.85%
Return on Assets (ttm)
-10.61%
Return on Equity (ttm)
-54.02%
Revenue (ttm)
367.79M
Net Income Avi to Common (ttm)
-411.38M
Diluted EPS (ttm)
-0.260
Balance Sheet and Cash Flow
Total Cash (mrq)
475.99M
Total Debt/Equity (mrq)
124.69%
Levered Free Cash Flow (ttm)
-185.08M